Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025648 · ClinicalTrials.gov registry record · Phase 1
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
A Phase 1 study, sponsored by Amphastar Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01025648: Clinical Trial Phase 1 study, sponsored by Amphastar Pharmaceuticals.
NCT01025648 is a Phase 1 study that was terminated before completion, run by Amphastar Pharmaceuticals. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01025648, a Phase 1 study, was terminated before completion, sponsored by Amphastar Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to identify the optimum E004 dose strength(s) for the ensuing pivotal clinical trials. The study will be conducted in adult patients who have intermittent, or mild-to-moderate persistent, asthma, but are otherwise healthy. The bronchodilatory efficacy of E004, is evaluated in terms of post-dose area under the curves (AUC) of FEV1 changes (% and volumes), from the pre-dose baseline values, in comparison to the Placebo Control and the Active Control.
Interventions
- DRUG E004 (epinephrine inhalation aerosol), 90 mcg/actuation
- DRUG E004 Placebo
- DRUG E004 (epinephrine inhalation aerosol), 125 mcg
- DRUG E004 (epinephrine inhalation aerosol), 220 mcg
- DRUG epinephrine inhalation aerosol, CFC propelled
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Why NCT01025648 stopped before completion
NCT01025648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which E004 (epinephrine inhalation aerosol), 90 mcg/actuation is the first listed.
NCT01025648 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01025648 about?
NCT01025648 is a clinical study titled "Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.". The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to identify the optimum E004 dose strength(s) for the ensuing pivotal clinica...
What is the current status of trial NCT01025648?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2009-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT01025648?
The interventions under investigation include: E004 (epinephrine inhalation aerosol), 90 mcg/actuation (DRUG), E004 Placebo (DRUG), E004 (epinephrine inhalation aerosol), 125 mcg (DRUG), E004 (epinephrine inhalation aerosol), 220 mcg (DRUG), epinephrine inhalation aerosol, CFC propelled (DRUG).
Who is sponsoring clinical trial NCT01025648?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01025648's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia